profit from every $100 of sales.
$0$100
Radiopharm Theranostics
$0.76-3.80% today
-83.3% in 1 year
1-year low $0.761-year high $10.63
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Radiopharm Theranostics sold, what it kept, and what it did with the cash.
Sales went from A$8,831 in 2022 to A$3.63 million in 2025, with -A$38.3 million of profit last year.
SalesProfit
Radiopharm Theranostics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Radiopharm Theranostics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Radiopharm Theranostics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 4 | |
| 0 | 0 | 0 | 0 | |
| -20 | -32 | -37 | -35 | |
| -18 | -34 | -47 | -38 | |
| -30 | -35 | -48 | -38 | |
| -45.85 | -32.07 | -37.23 | -5.28 | |
| 100.0% | 100.0% | 100.0% | 1.1% | |
| -225,527.7% | -10,839.6% | -12,423.3% | -953.4% | |
| -343,550.9% | -11,838.6% | -16,024.3% | -1,055.3% |
Balance sheet
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 83 | 75 | 72 | 86 |
| Cash | 27 | 12 | 19 | 29 |
| Total debt | – | – | – | – |
| Total liabilities | 20 | 29 | 45 | 44 |
| 63 | 44 | 28 | 45 | |
| 1 | 1 | 1 | 7 | |
| -26.3% | -61.4% | -132.6% | -67.3% | |
| -48.2% | -78.0% | -170.5% | -85.6% |
Cash flow
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| 28 | 2 | – | – | |
| -38 | -25 | -23 | -37 | |
| Dividends paid | – | – | – | – |
| 5 | 1 | 2 | – | |
| – | – | – | – |
Valuation
- –
- –
- –
- 0.9×
- 4.8×
- –
- –
- -208.0%
- -217.6%
- 0.0%
Profitability
- 1.1%
- -953.4%
- -1,055.3%
- -1,050.4%
- -53.4%
- -95.6%
- -105.2%
- -44.3%
- -53.4%
- 757.3%
Growth
- +643.8%
- –
- −59.5%
- –
- +89.5%
Financial health
- -0.8×
- 0.00
- 0.0%
- -584.6×
- 2.67
- 2.67
- 0.04
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 946
What analysts expect
- Average price target
- $14.00
- Range
- $13.00 – $15.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 27, 2026 | -2.25 | -1.51 | −49.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
71Pass
Philip Fisher
34No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
30No pass
Questions about Radiopharm Theranostics
Is Radiopharm Theranostics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Radiopharm Theranostics AI analysis
What does Radiopharm Theranostics do?
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is in Biotechnology.
Does Radiopharm Theranostics pay a dividend?
No. Radiopharm Theranostics does not pay a dividend at the moment.
Is Radiopharm Theranostics stock halal?
No. Radiopharm Theranostics does not pass our halal screen: its cash and confirmed interest-bearing investments are 165% of its market value, at or above the 33% limit. How we check
How has Radiopharm Theranostics stock done over the past year?
Down 83.3% over the past twelve months, to $0.76. It traded between $0.76 and $10.63 and is 92.9% below its high.
Who are Radiopharm Theranostics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Radiopharm Theranostics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.